welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

key information

study id #: NCT02525302

condition: Duchenne Muscular Dystrophy

status: terminated


This study, HALO-DMD-03, is a follow-on study to HALO-DMD-01 and HALO-DMD-02, and allows continued open-label access to HT-100 for subjects who have completed these studies. HALO-DMD-03 will provide safety and strength and function data on continuous long-term dosing. Data from this study will be used to inform the safety, tolerability, and dose selection for a future trial of HT-100 in boys with Duchenne Muscular Dystrophy (DMD).

intervention: HT-100

mechanism of action: Small molecule designed to reduce fibrosis and inflammation

results: https://clinicaltrials.gov/ct2/show/results/NCT02525302

last updated: April 01, 2019